The biotechnology company Biogen are seeking FDA approval of the drug Aducanumab for treatment of early Alzheimer’s disease.
Prof Bart De Strooper, Director of the UK Dementia Research Institute, University College London (UCL), said:
“It is fantastic to hear of these new positive results emerging from the aducanumab trials. We currently have no effective treatments to slow or halt the progression of Alzheimer’s disease and I hope this signifies a turning point.
“It is encouraging for the field that the tremendous work delivered to target amyloid beta appears to be validated in this trial and we should now redouble our efforts to tackle this central problem in Alzheimer’s Disease, alongside other important contributors.
“The results demonstrate that evaluation of our trial strategies and analysis must be ongoing. As with other medicines, there are subtle but critical differences between individuals, and this can have a huge effect on response to treatments.”